Trial Profile
Phase I/II study of S-1 plus intravenous and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jun 2019
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Cancer metastases; Pancreatic cancer
- Focus Therapeutic Use
- 30 May 2015 Status changed from recruiting to active no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 21 Dec 2012 New trial record